
-
Jeep owner Stellantis suspends 2025 earnings forecast over tariffs
-
China's Shenzhou-19 astronauts return to Earth
-
French economy returns to thin growth in first quarter
-
Ex-Premier League star Li Tie loses appeal in 20-year bribery sentence
-
Belgium's green light for red light workers
-
Haliburton leads comeback as Pacers advance, Celtics clinch
-
Rahm out to break 2025 win drought ahead of US PGA Championship
-
Japan tariff envoy departs for round two of US talks
-
Djurgarden eyeing Chelsea upset in historic Conference League semi-final
-
Haliburton leads comeback as Pacers advance, Pistons stay alive
-
Bunker-cafe on Korean border paints image of peace
-
Tunics & turbans: Afghan students don Taliban-imposed uniforms
-
Asian markets struggle as trade war hits China factory activity
-
Norwegian success story: Bodo/Glimt's historic run to a European semi-final
-
Spurs attempt to grasp Europa League lifeline to save dismal season
-
Thawing permafrost dots Siberia with rash of mounds
-
S. Korea prosecutors raid ex-president's house over shaman probe: Yonhap
-
Filipino cardinal, the 'Asian Francis', is papal contender
-
Samsung Electronics posts 22% jump in Q1 net profit
-
Pietro Parolin, career diplomat leading race to be pope
-
Nuclear submarine deal lurks below surface of Australian election
-
China's manufacturing shrinks in April as trade war bites
-
Financial markets may be the last guardrail on Trump
-
Swedish journalist's trial opens in Turkey
-
Kiss says 'honour of a lifetime' to coach Wallabies at home World Cup
-
US growth figure expected to make for tough reading for Trump
-
Opposition leader confirmed winner of Trinidad elections
-
Snedeker, Ogilvy to skipper Presidents Cup teams: PGA Tour
-
Win or bust in Europa League for Amorim's Man Utd
-
Trump celebrates 100 days in office with campaign-style rally
-
Top Cuban dissidents detained after court revokes parole
-
Arteta urges Arsenal to deliver 'special' fightback against PSG
-
Trump fires Kamala Harris's husband from Holocaust board
-
Pakistan says India planning strike as tensions soar over Kashmir attack
-
Weinstein sex attack accuser tells court he 'humiliated' her
-
France accuses Russian military intelligence over cyberattacks
-
Global stocks mostly rise as Trump grants auto tariff relief
-
Grand Vietnam parade 50 years after the fall of Saigon
-
Trump fires ex first gentleman Emhoff from Holocaust board
-
PSG 'not getting carried away' despite holding edge against Arsenal
-
Cuban dissidents detained after court revokes parole
-
Sweden stunned by new deadly gun attack
-
BRICS blast 'resurgence of protectionism' in Trump era
-
Trump tempers auto tariffs, winning cautious praise from industry
-
'Cruel measure': Dominican crackdown on Haitian hospitals
-
'It's only half-time': Defiant Raya says Arsenal can overturn PSG deficit
-
Dembele sinks Arsenal as PSG seize edge in Champions League semi-final
-
Les Kiss to take over Wallabies coach role from mid-2026
-
Real Madrid's Rudiger, Mendy and Alaba out injured until end of season
-
US threatens to quit Russia-Ukraine effort unless 'concrete proposals'

Biden proposes huge expansion of weight loss drug access
Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald Trump's incoming health chief looked set to shoot down the idea.
Under the massive US public health insurance programs Medicare and Medicaid, drugs like Ozempic and Wegovy are, for the most part, only available for overweight people with diabetes or heart disease.
But the White House said Biden wanted to make the game-changing medications widely available as a treatment for obesity itself -- expanding coverage to nearly 7.5 million older and lower-income Americans.
"For too many Americans, these critical treatments are too expensive and therefore out of reach," a White House official said, noting that 42 percent of Americans are obese.
The Department of Health and Human Services said separately in a statement that the "transformative medications" would improve the "health and quality of life for millions of people who have obesity."
The move would benefit 3.4 million Americans with Medicare, which gives health insurance to people mainly aged over 65. It would also help four million people eligible for assistance with Medicaid, which targets lower income residents, officials said.
But the last-gasp plan appears unlikely to survive given that Trump's incoming health secretary, Robert F. Kennedy Jr., has previously spoken out against the use of anti-obesity drugs.
In October Kennedy opposed a separate bill in Congress that would have expanded access to the medications, saying the money needed to do that would be better spent on improving nutrition.
"If we spent about one fifth of that giving good food, three meals a day to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight," Kennedy said on Fox News.
- 'So stupid' -
He also accused the Danish makers of Ozempic and Wegovy, Novo Nordisk, of "counting on selling it to Americans, because we're so stupid and addicted to drugs."
Kennedy has attracted major controversy for his anti-vaccine activism and embrace of conspiracy theories -- but some of his proposals for improving American's diets have won praise from health campaigners and lawmakers.
Any plan to increase US public health insurance spending would also likely run foul of Trump's bid to slash government budgets and waste.
Trump said last week as he appointed celebrity TV doctor Mehmet Oz to head Medicare and Medicaid that Oz would "cut waste and fraud" in what he called "our Country's most expensive Government Agency."
The Republican has also named tech tycoon Elon Musk and entrepreneur Vivek Ramaswamy to head a so called "government efficiency" commission to cut costs across government.
Biden has taken a different tack during his sole term in office.
The Democrat has led a major drive to lower the exorbitant cost of US prescription medicines, and his success in forcing pharmaceutical giants to reduce the prices of some became a key plank of his reelection campaign before he dropped out in July.
In July, Biden called on Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs, saying firms must stop "ripping off the American people."
N.Schaad--VB